Gene · 8438
Papers1,865
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 1,865
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The pan-cancer analysis identified DIAPH3 as a diagnostic biomarker of clinical cancer. | Aging (Albany NY) | 2023 | 36750200 | PubTator, text mining | PubMed |
| Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study. | Cancer Sci | 2023 | 36747324 | PubTator, text mining | PubMed |
| Sequential genome-wide CRISPR-Cas9 screens identify genes regulating cell-surface expression of tetraspanins. | Cell Rep | 2023 | 36724073 | PubTator, text mining | PubMed |
| Germline-related molecular phenotype in Metazoa: conservation and innovation highlighted by comparative transcriptomics. | Evodevo | 2023 | 36717890 | PubTator, text mining | PubMed |
| The effects of altered DNA damage repair genes on mutational processes and immune cell infiltration in esophageal squamous cell carcinoma. | Cancer Med | 2023 | 36708047 | PubTator, text mining | PubMed |
| DNA Damage Response and Repair in Boron Neutron Capture Therapy. | Genes (Basel) | 2023 | 36672868 | PubTator, text mining | PubMed |
| CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. | Nat Commun | 2023 | 36650183 | PubTator, text mining | PubMed |
| Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer. | JCO Precis Oncol | 2023 | 36623239 | PubTator, text mining | PubMed |
| Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations. | Hum Genomics | 2023 | 36604691 | PubTator, text mining | PubMed |
| EIF3D promotes resistance to 5-fluorouracil in colorectal cancer through upregulating RUVBL1. | J Clin Lab Anal | 2023 | 36592991 | PubTator, text mining | PubMed |
| Pol X DNA polymerases contribute to NHEJ flexibility. | Nat Struct Mol Biol | 2023 | 36587186 | PubTator, text mining | PubMed |
| PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study. | Asian J Androl | 2023 | 36537376 | PubTator, text mining | PubMed |
| RMI2 is a novel prognostic and predictive biomarker for breast cancer. | Cancer Med | 2023 | 36533385 | PubTator, text mining | PubMed |
| Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. | Toxicol Sci | 2023 | 36519830 | PubTator, text mining | PubMed |
| DNA repair/recombination protein 54L promotes the progression of lung adenocarcinoma by activating mTORC1 pathway. | Hum Cell | 2023 | 36454390 | PubTator, text mining | PubMed |
| Multifaceted Influence of Histone Deacetylases on DNA Damage Repair: Implications for Hepatocellular Carcinoma. | J Clin Transl Hepatol | 2023 | 36406320 | PubTator, text mining | PubMed |
| Single-cell RNA-seq analysis to identify potential biomarkers for diagnosis, and prognosis of non-small cell lung cancer by using comprehensive bioinformatics approaches. | Transl Oncol | 2023 | 36401966 | PubTator, text mining | PubMed |
The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study. | Cancer Med | 2023 | 36358026 | PubTator, text mining | PubMed |
| Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA. | Clin Cancer Res | 2023 | 36318705 | PubTator, text mining | PubMed |
| Triple-negative Thrombocythemia and Subsequent Acute Lymphoblastic Leukemia with Additional Somatic Mutations. | Intern Med | 2023 | 36104197 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8438/papers?page=14